SS, S., & A, K. (2016). Sodium–glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: Focus on dapagliflozin–metformin. Dove Medical Press.
Chicago Style (17th ed.) CitationSS, Schwartz, and Katz A. Sodium–glucose Cotransporter-2 Inhibitor Combination Therapy to Optimize Glycemic Control and Tolerability in Patients with Type 2 Diabetes: Focus on Dapagliflozin–metformin. Dove Medical Press, 2016.
MLA (8th ed.) CitationSS, Schwartz, and Katz A. Sodium–glucose Cotransporter-2 Inhibitor Combination Therapy to Optimize Glycemic Control and Tolerability in Patients with Type 2 Diabetes: Focus on Dapagliflozin–metformin. Dove Medical Press, 2016.
Warning: These citations may not always be 100% accurate.